OpenDNA, a leader in AI-based precision medicine, today announced the successful conclusion of a clinical study evaluating its AI-powered cardiovascular risk prediction platform. Conducted across three clinics in Maryland and New Jersey, the study enrolled 150 patients with diverse risk factors to assess the platform’s utilization, accuracy, and clinical impact.
The study demonstrated the potential of OpenDNA’s deep learning–driven solution to transform cardiovascular care by enabling earlier and more precise risk identification.
“We are very pleased with this study,” said Dr. Michael Chen, MD, FACC, FSCAI, RPVI, Interventional Cardiologist at Adventist HealthCare Cardiac Associates. “The utilization, accuracy, impact, and precision of the OpenDNA platform have the potential to revolutionize the way we diagnose and treat CVD. We believe that OpenDNA’s AI-powered platform can help clinicians identify patients at high risk and provide the care they need to prevent or delay disease.”
OpenDNA’s platform integrates genetic and clinical data to deliver a personalized cardiovascular risk score for each patient. By applying advanced deep learning algorithms to both DNA profiles and non-genetic clinical data, the system identifies hidden patterns associated with cardiovascular risk—empowering physicians to deliver more proactive and personalized care.
The clinical study highlighted the platform’s ability to operate effectively across diverse populations, incorporating variables such as age, gender, race, ethnicity, family history, and lifestyle factors. Results reinforce the value of AI in augmenting traditional clinical approaches to cardiovascular risk assessment.
Already in use by clinicians in the United States, Europe, and Israel, the OpenDNA platform is commercially available and deployed across primary care and concierge medicine practices. The company plans to expand its clinical trial program to further validate the utilization, precision, and scalability of its AI-powered cardiovascular risk prediction technology.
